

FEB 28 2002

JC05 R-1 PCT/PTO 28 FEB 2002

Docket No. 215869US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nobuya MATSUOKA, et al.

SERIAL NO: 09/926,641

GAU:

FILED: November 28, 2001

EXAMINER:

FOR: AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING
COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Surinder Sachar

Norman F. Oblon

Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)

Surinder Sachar

Registration No. 34,423



LIST OF RELATED CASES

<u>Docket Number</u>	<u>Serial or Patent No.</u>	<u>Filing or Issue Date</u>	<u>Status or Patentee</u>
0018-1058-0	6,344,358	02/05/02	MATSUOKA, et al.
217312US0 DIV	10/041,592	01/10/02	PENDING
215869US0 PCT*	09/926,641	11/28/01	PENDING

*Present application; listed for information.

O
JC98
FEB 28 2002
PATENT & TRADEMARK OFFICE

Form PTO 1449 (Modified) LIST OF REFERENCES CITED BY APPLICANT		ATTY DOCKET NO. 215869US0PCT		SERIAL NO. 09/926,641	
		APPLICANT Nobuya MATSUOKA, et al.			
		FILING DATE November 28, 2001		GROUP	
		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
AA					
AB					
AC					
AD					
AE					
AF					
AG					
AH					
AI					
AJ					
AK					
AL					
AM					
AN					
FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
	AO 98 25914	06/18/98	WO	YES	NO
	AP 00 42011	07/20/00	WO		No
	AQ 98 35951	08/20/98	WO		No
	AR 0 436 734	07/17/91	EP		No
	AS 97 36871	10/09/97	WO		No
	AT 99 55674	11/04/99	WO		No
	AU				
	AV				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
AW	Nobuya MATSUOKA et al.: "FK960 'N-(4-acetyl-1-piperazinyl)-p-fluorobenzam antideementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine" J. PHARMACOL. EXP. THER., 280(3), pages 1201-1209 1997				
AX	A. GRAUL et al.: "FK-960. Cognition enhancer." DRUGS FUTURE, 22(8), pages 830-832 1997				
AY	Nobuya MATSUOKA et al.: "FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices" BRAIN RESEARCH, vol. 794, no. 2, pages 248-254 06/01/98				
AZ				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered	

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.